Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn’s Disease: A Case Report and Review of the Literature

References

• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of Spondylo Arthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783. doi:10.1136/ard.2009.10823319297344
   PubMed Web of Science ®Google Scholar
• Gill T, Asquith M, Rosenbaum JT, Colbert RA. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol. 2015;27(4):319–325. doi:10.1097/BOR.000000000000018726002022
   PubMed Web of Science ®Google Scholar
• Mustafa KN, Hammoudeh M, Khan MA. HLA-B27 prevalence in Arab populations and among patients with ankylosing spondylitis. J Rheumatol. 2012;39(8):1675–1677. doi:10.3899/jrheum.12040322753660
   PubMed Web of Science ®Google Scholar
• Tanaka H, Akaza T, Juji T. Report of the Japanese central bone marrow data center. Clin Transpl. 1996;139–144.9286563
   PubMedGoogle Scholar
• Malaty HM, Lo GH, Hou JK. Characterization and prevalence of spondyloarthritis and peripheral arthritis among patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2017;10:259–263. doi:10.2147/CEG.S13638329026327
   PubMed Web of Science ®Google Scholar
• Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004;20(10):1035–1043. doi:10.1111/j.1365-2036.2004.02270.x15569105
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(2):196–202. doi:10.1016/S1542-3565(05)00980-816469680
   PubMed Web of Science ®Google Scholar
• Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563–2574. doi:10.1056/NEJMra140618227355535
   PubMed Web of Science ®Google Scholar
• Pouillon L, Bossuyt P, Vanderstukken J, et al. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017;10(12):1363–1374. doi:10.1080/17512433.2017.137760928879780
   PubMed Web of Science ®Google Scholar
• Torgutalp M, Poddubnyy D. Emerging treatment options for spondyloarthritis. Best Pract Res Clin Rheumatol. 2018;32(3):472–484. doi:10.1016/j.berh.2019.01.01431171316
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18–24. doi:10.1136/ard.2008.09487018625618
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–2291.7699630
   PubMed Web of Science ®Google Scholar
• Ephgrave K. Extra-intestinal manifestations of Crohn’s disease. Surg Clin North Am. 2007;87(3):673–680. doi:10.1016/j.suc.2007.03.00317560419
   PubMed Web of Science ®Google Scholar
• Shorbagi A, Bayraktar Y. Primary sclerosing cholangitis–what is the difference between east and west? World J Gastroenterol. 2008;14(25):3974–3981. doi:10.3748/wjg.14.397418609680
   PubMed Web of Science ®Google Scholar
• Peeters H, Vander Cruyssen B, Mielants H, et al. Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol. 2008;23(1):132–137. doi:10.1111/j.1440-1746.2007.05108.x17725592
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258–270. doi:10.1002/art.4072830225992
   PubMed Web of Science ®Google Scholar
• Otsuka A, Morita M, Yamada H. Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab. J Orthop Sci. 2015;20(6):1070–1077. doi:10.1007/s00776-015-0755-z26245191
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Linden S, Juhlin R, et al. The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218–1227. doi:10.1002/art.17803410031930310
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Ohishi M, Okazaki K, et al. Delayed diagnosis of ankylosing spondylitis in a Japanese population. Mod Rheumatol. 2016;26(3):421–425. doi:10.3109/14397595.2015.108867926382224
   PubMed Web of Science ®Google Scholar
• Goh L, Samansa A. Update on biologic therapies in ankylosing spondylitis: a literature review. Int J Rheum Dis. 2012;15(5):445–454. doi:10.1111/j.1756-185X.2012.01765.x23083034
   PubMed Web of Science ®Google Scholar
• Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N. Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol. 2017;13(6):359–367. doi:10.1038/nrrheum.2017.5628446810
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–1076. doi:10.1038/nm.281722772566
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–823. doi:10.1136/annrheumdis-2013-20424824389297
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease. Biologics. 2018;12:69–73. doi:10.2147/BTT.S16932630050284
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Verstockt B, Gils A, et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13(11):1401–1409. doi:10.1093/ecco-jcc/jjz08030989232
   PubMed Web of Science ®Google Scholar
• Mease P. Ustekinumab fails to show efficacy in a phase III axial spondyloarthritis program: the importance of negative results. Arthritis Rheumatol. 2019;71(2):179–181. doi:10.1002/art.4075930600936
   PubMed Web of Science ®Google Scholar
• Chateau T, Angioi K, Peyrin-Biroulet L. Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn’s disease. J Crohns Colitis. 2020;14(4):571. doi:10.1093/ecco-jcc/jjz16731606743
   PubMed Web of Science ®Google Scholar